Clearside Biomedical, Inc. Reports Second Quarter 2016 Financial Results
11 août 2016 07h00 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces Promotion of Glenn Noronha, Ph.D. to Chief Scientific Officer and Jennifer M. Kissner, Ph.D. to Vice President, Clinical Development
01 août 2016 07h00 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
26 juil. 2016 07h30 HE
|
Clearside Biomedical, Inc.
78% of Patients Required No Additional Treatment in the Trial Arm with Concomitant Suprachoroidally Administered Zuprata™ and Intravitreally Administered Eylea®Patients Reached an Average BCVA...